Navigation Links
San Antonio Investigators Report on Mountain Cedar Allergy Model
Date:7/25/2013

San Antonio, TX (PRWEB) July 25, 2013

In the July 2013 issue of the Annals of Allergy, Asthma and Immunology, investigators in San Antonio, Texas describe the use of the mountain cedar season as a valuable tool for the assessment of new allergy medications and vaccines. The article, entitled "The mountain cedar model in clinical trials of seasonal allergic rhinoconjunctivitis," discusses the immune features of the pollen, reviews published studies and presents the daily pollen grain counts recorded over 18 years.

Dr. Charles Andrews, a Principal Investigator of the Biogenics Research Chamber and the lead author of the article notes that, “the mountain cedar pollen tsunami hits south-central Texas annually with a ferocity and dependability that have made the season a mainstay in allergy research.”

Thirty-eight studies from the scientific literature are presented, recognizing that many other studies, particularly generic drug trials, are unpublished. Analysis of the pollen counts provided by Dr. Paul Ratner reveals uniformity over many years that allows advance planning for successful natural season trials. Mountain cedar pollen has also been found to elicit major nasal and eye symptoms in multiple studies in the Biogenics Research Chamber. Utilizing mountain cedar pollen in the chamber model provides controlled trials for the evaluation of medications and vaccines, as well as allowing study of the basic inflammatory mechanisms of acute allergic reactions.

About the Company:

Biogenics Research Chamber located in San Antonio, Texas is the only large permanent pollen exposure testing facility in the United States. Dr. Robert Jacobs, Dr. Daniel Ramirez and Dr. Charles Andrews are the owners and Principal Investigators. The facility has a large chamber capable of testing up to 60 allergic participants at a time and a moderate sized chamber for testing up to 32 subjects. Both chambers utilize unique engineering and pollen delivery systems. Two additional chambers are being constructed. Compared to natural season allergy studies, the chambers offer controlled conditions without pollen concentration variation and weather interruptions. Proof of concept, dose-ranging, and onset of action studies are performed for pharmaceutical and vaccine trials. In addition to commercial studies, the Biogenics Research Chamber has performed multiple academic trials examining the basic mechanisms of allergy.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10958220.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Texas Fertility Center Opens New Fertility Clinic in San Antonio
2. Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
3. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
4. Agendia to Present Five Abstracts at 2011 San Antonio Breast Cancer Symposium
5. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
6. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
7. Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2013
8. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
9. Global Printed and Flexible Sensors 2013 Report: Forecasts, Players, Opportunities
10. China Pharmaceutical Industry Examined in New Kelly Scientific Publications Report Available at MarketPublishers.com
11. Global Activated Carbon Market 2012-2016: Latest Market Share, Growth, Analysis, Size, Trends & Forecast Research Report 2012-2016 Available at Marketresearchreports.biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):